The global anticoagulants market was valued at US$ 33,150.7 Mn in 2017 and expected to grow at compound annual growth rate (CAGR) of 6.6% during the forecast period from 2018 to 2026. Anticoagulants are prescribed to patients who are at higher risk of clot formation in the blood and reduce the risk of serious conditions such as strokes and heart attacks. Anticoagulants are also given to treat pulmonary embolism, deep vein thrombosis (DVT), atrial fibrillation and other cardiovascular diseases. Thus, increasing prevalence of cardiovascular diseases, especially DVT, atrial fibrillation and peripheral artery diseases is a major growth factor assisting the market. Launch of several novel oral anticoagulants (NOACs) with improved properties in the last decade has completely changed the market scenario over the years. Warfarin a vitamin K antagonists was the most preferred anticoagulants earlier as it was efficient in inhibiting the vitamin K recycling. However, use of warfarin had certain limitations such as continuous monitoring of international normalized ratio (INR) i.e. drug levels and drug-food & drug-drug interactions, acting as the drawbacks for the market.
NOACs are also referred as non-vitamin K antagonist oral anticoagulants, consisting for coagulation factors Xa inhibitors, factor IIa inhibitors and direct thrombin inhibitors which has faster onset of drug and lowered side effects compared to other drugs. The currently marketed NOACs include babigatran (Pradaxa), rivaroxaban (Xarelto), apixaban (Eliquis), edoxaban (Lixiana/Savaysa) and betrixaban (Bevyxxa). Xarelto by Bayer/ Janssen Pharmaceuticals and Eliquis by Pfizer/ Bristol-Myers Squibb are the most prescribed NOACs globally owing to impressing efficacy rate in the trials, lower side-effects such as uncontrollable bleeding and the ability of the drugs to treat multiple indications, provide an upper hand in the market. Bevyxxa by Portola Pharmaceuticals was the latest addition in the market, getting U.S. Food and Drug Administration (FDA) approval in June 2017 and launched in January 2018 for prophylaxis of venous thromboembolism (VTE). This will further drive the market for anticoagulants market.
Market Synopsis
Get a sample copy for more information
"Novel Oral Anticoagulants Will Drive the Anticoagulants Market During the Forecast Period"
In 2017, NOACs held the largest share of more than 50% of the overall anticoagulants market. The segment is projected to exhibit fastest growth rate during the forecast period as NOACs provides higher advantage over vitamin K antagonist in terms of safety, lower side effects such as bleeding episodes, decreased need for continuous dosage monitoring and availability of anticoagulant reversal agents. Higher prices of NOACs as compared to other drug segment also leads to the growth of the market.
Get a sample copy for more information
Historical & Forecast Period
This research report presents the analysis of each segment from 2016 to 2026 considering 2017 as the base year for the research. Compounded annual growth rate (CAGR) for each respective segments calculated for the forecast period from 2018 to 2026.
Report Scope by Segments
Anticoagulants market report furnishes quantitative analysis along with its latest market trends. The market is segmented based on drug class, application and geography.
| ATTRIBUTE |
DETAILS |
| Research Period |
2016-2026 |
| Base Year |
2017 |
| Forecast Period |
2018-2026 |
| Historical Year |
2016 |
| Unit |
USD Million |
| Segmentation |
By Drug Class (2016–2026; US$ Mn)
• Novel Oral Anticoagulants (NOACs)
• Vitamin K Antagonists
• Heparins & Low Molecular Weight Heparins (LMWH)
• Antiplatelet Agents
• Thrombolytic Agents
• Direct Thrombin Inhibitors
|
|
By Application (2016–2026; US$ Mn)
• Atrial Fibrillation & Heart Attacks
• Strokes
• Deep Vein Thrombosis (DVT)
• Pulmonary Embolism
|
|
Geography Segment (2016–2026; US$ Mn)
• North America (U.S., Canada)
• Europe (U.K., Germany, Rest of Europe)
• Asia Pacific (China, Japan, Rest of APAC)
• Latin America (Brazil, Mexico, Rest of Latin America)
• Middle East and Africa (GCC, Rest of Middle East and Africa)
|
Market is studied in order to understand the current dynamics and future trends in the global anticoagulants market. The study includes market size and forecast for all considered segments presented in the report for the period from 2016 to 2026, along with respective compound annual growth rate (CAGRs) for the forecast period from 2018 to 2026, considering 2017 as the base year. The key players currently engaged in anticoagulants market include Bayer AG, Janssen Pharmaceuticals, Inc., Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Pfizer, Inc., Daiichi Sankyo Company Limited, and Portola Pharmaceuticals, Inc. among others.
Get a sample copy for more information
Key questions answered in this report
- How the global anticoagulants market will perform during the forecast period from 2018 to 2026?
- What are the latest trends in the anticoagulants market and valuable opportunities for key players?
- Who are the leading players in the global anticoagulants market?
- Which is the leading and fastest region in the global anticoagulants market?
- What are drivers and restrains governing the global anticoagulants market?
